Premium
Production of phospholipid antibodies in selected thrombophilic women differing in genotype at the 506 site of factor V
Author(s) -
Bokarewa Maria I.,
Bremme Katarina
Publication year - 1998
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1998.tb01056.x
Subject(s) - antibody , lupus anticoagulant , genotype , phosphatidylserine , medicine , microbiology and biotechnology , factor v , thrombophilia , endocrinology , immunology , phospholipid , biology , genetics , thrombosis , gene , membrane
The composition of antibodies against phospholipids (PLa) was analysed in 54 PLa‐positive thrombophilic women, different in the factor V genotype (Arg 506 ‐Gln mutation carriers, n = 23; and noncarriers, n = 31). The presence of antibodies against prothrombin was also studied. The incidence of cardiolipin antibodies (CLa) and lupus anticoagulant (LA) activity was similar among the carriers and noncarriers, while phosphatidylserine antibodies (PSa) were often the only PLa detected in the carriers of the mutation (7/23 vs. 2/31; χ 2 = 5.47, p < 0.05). Antibodies against prothrombin were found in 11 of 54 patients. They segregated with PSa (8/19 vs. 3/35; χ 2 = 8.54, p < 0.025), but were equally distributed between carriers and noncarriers. The analysis of nAPC‐ratio in patients with different PLa showed that it was consistently lower in the mutation carriers in whom none of the PLa caused further suppression. The noncarrier group positive for LA in several assays was associated with a reduction of nAPC‐ratio (0.82 ± 0.25 vs. 1.12 ± 0.22, p < 0.05). Our findings indicate that PLa contributing to the development of APC resistance are restricted to those possessing LA activity.